The STAT3 inhibitor TTI-101 was shown to effectively inhibit tumor growth in SMARCB1-deficient BLCA patient-derived xenograft mice without significant weight loss, providing a strong preclinical rationale for using TTI-101 as a therapeutic strategy for SMARCB1-deficient BLCA. Here, STAT3 is linked to bladder transitional cell carcinoma.